Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents

  • US 7,871,597 B2
  • Filed: 04/09/2003
  • Issued: 01/18/2011
  • Est. Priority Date: 04/09/1999
  • Status: Active Grant
First Claim
Patent Images

1. A unit dosage of a pharmacological composition comprising a terminally sterilizable autoclavable reduced carboxymethylated dextran iron oxide complex composition which is stable at 121 C and is prepared,in a total volume of biocompatible liquid from about 1 mL to about 15 mL and for a total single dose from about 50 mg to about 600 mg, the pharmacological composition capable of being parenterally administered to a subject at a rate substantially greater than 1 mL/min and wherein the unit dosage provides upon administration:

  • minimal detectable free iron in the subject; and

    minimal incidence of anaphylaxis.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×